DNA Therapies Could Make Better Treatment for Mesothelioma in Comparison to Standard Cancer Treatment
Cancer doctors determine what kind of treatment to pursue to each patient. The options are endless. There exists no standard treatment option for mesothelioma victims. Mesotheliomas lack of agreed-upon treatment is due to low a treatment success rate, rareness, a high mortality rate and a small number of studies providing meaningful stats.
The prospects for mesothelioma patients have been grim, but doctors have recently made progress. Treatments for cancer are traditionally surgery (taking out the tumor and surrounding tissue), chemotherapy (poisoning cancerous cells) and radiation (killing cancer cells with radiation) There are problems with all three. Mesothelioma patients treated with traditional radiation therapy have not responded well to it. In hopes to lessen damage to healthy tissue, researches are studying ways to aim radiation right at the tumor.
Surgery takes out the mesothelial cancerous tissue around the tumor. This surgery is extensive and it is not clear how much the patient benefits. The usual chemotherapy cocktails effective on other cancers are not effective on mesothelioma, and combinations of chemotherapy agents have been tried, but without much success. Like radiation, researchers are focusing their work on controlling the physical location of the treatment with an emphasis on the pleural cavity.
Many advanced techniques in cancer treatment are tried on mesothelioma patients because of its high fatality rate. These techniques include a biologic therapy called the agent interleukin 2 and anti-angiogenesis drugs like thalidomide. A new drug that has shown results in improving survival is pemetrexed (brand name Alimta).
Before acting, oncologists review the stage of mesothelioma, position of the tumor, and age and health status of the patient. Two exotic ways of attacking mesothelioma are gene therapy and photodynamic therapy. Patients afflicted with mesothelioma are benefitting in these clinical trials.
